Davis's Drug Guide for Mobile + Web by Unbound Medicine, Inc.

Davis's Drug Information for Cellular + Web Screenshots

Description

Features NEW 13th variation monographs
== PLEASE NOTE: Application requires a paid subscription to the web Daviss Drug Guide provider. ==

** CURRENT Daviss Drug Information for Cell + interNet subscribers can obtain content to their iOS instrument without charge **

The thirteenth version of Daviss Drug Guide for Cell + Net can provide depended on, complete, sensible knowledge on over 5,000 exchange identify and prevalent drugs on your iPhone, iPad, iPod contact, and the online. This powerful app, with its center of attention on security, comprises everything you want to present better patient care, including data on dosing and administration, interactions, and patient teaching.

Daviss Drug Guide for Cellular + Net includes:
Over 5,000 trade title and normal drug listings
High-alert notices
Risk Analysis and Mitigation Methods (REMS), highlighted by means of an icon
Drug-drug, drug-natural, and drug-meals interactions
Discontinued drug list
Distinctive optimization for iPad, iPhone, and iPod contact interfaces
Common Index Search in finding phrases throughout all indexes
Favorites for bookmarking important entries
Regular updates and interNet get right of entry to for three hundred and sixty five days

How It Works
___________
Present day Daviss Drug Guide for Mobile + Web subscribers:
Install the application to your iOS software.
Open the applying and enter your Daviss Drug Information for Cell + interNet username and password, then tap Login.
The latest Daviss Drug Guide content can be downloaded to your gadgets over your wireless connection.

Writer: F.A. Davis Firm
Powered via: Unbound Medicine

What's New in Version 1.eleven

* Updated utility

Extra Apps by means of Unbound Medication, Inc.
Davis's Drug Gu..	Harriet Lane Ha..	Johns Hopkins A..	5 Minute Clinic..	The Merck Manua..

Clients Also Sold
Lexicomp	Mediquations M..	MediMath Medic..	Scientific Spanis..	AbbStore-Lite ..

Comments